Singapore - English - HSA (Health Sciences Authority)

ucb trading (sg) pte. ltd. - certolizumab pegol (cdp870) - injection, solution - 200 mg/ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ucb pharma ltd - certolizumab pegol - solution for injection - 200mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

ucb pharma ltd - certolizumab pegol - solution for injection - 200mg/1ml

European Union - English - EMA (European Medicines Agency)

ucb pharma sa  - certolizumab pegol - arthritis, rheumatoid - immunosuppressants - rheumatoid arthritiscimzia, in combination with methotrexate (mtx), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmards) including mtx, has been inadequate. cimzia can be given as monotherapy in case of intolerance to mtx or when continued treatment with mtx is inappropriatethe treatment of severe, active and progressive ra in adults not previously treated with mtx or other dmards.cimzia has been shown to reduce the rate of progression of joint damage as measured by x ray and to improve physical function, when given in combination with mtx.axial spondyloarthritis cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising:ankylosing spondylitis (as)adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (nsaids).axial spondyloarthritis without radiogra

Canada - English - Health Canada

ucb canada inc - certolizumab pegol - solution - 200mg - certolizumab pegol 200mg - miscellaneous gi drugs

Canada - English - Health Canada

ucb canada inc - certolizumab pegol - solution - 200mg - certolizumab pegol 200mg - miscellaneous gi drugs

Israel - English - Ministry of Health

neopharm ltd, israel - certolizumab pegol - solution for injection - certolizumab pegol 200 mg/ml - certolizumab pegol - rheumatoid arthritis:cimzia, in combination with methotrexate (mtx), is indicated for: the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate, has been inadequate. cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.axial spondyloarthritis:cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising: ankylosing spondylitis (as): adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (nsaids). axial spondyloarthritis without radiographic evidence of as adults with severe active axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated c reactive protein (crp) and /or magnetic resonance imaging (mri), who have had an inadequate response to, or are intolerant to nsaids. crohn's disease :cimzia is indicated for reducing signs and symptoms of crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.plaque psoriasis:cimzia is indicated for the treatment of moderate to severe plaque psoriasis in adults who arecandidates for systemic therapy.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

u.c.b., belgium - certolizumab pegol - solution for injection - 200 mg

European Union - English - EMA (European Medicines Agency)

ucb pharma sa - certolizumab pegol - crohn disease - immunosuppressants - cimzia, in combination with methotrexate (mtx), is indicated for the treatment of moderate to severe, active rheumatoid arthritis (ra) in adult patients when the response to disease-modifying antirheumatic drugs (dmard) including methotrexate, has been inadequate.cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.cimzia has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.